Moderna Announces Plan to Expand Commercial Footprint in Europe Across Six Additional Countries - Seite 2

The Company currently has operations in 12 countries worldwide and has announced plans to establish a commercial presence in another ten countries across Asia-Pacific and Europe in 2022. Regulators have approved Moderna's COVID-19 vaccine in more than 70 countries, including Canada, Japan, the European Union, the UK, and Israel. In 2021, 807 million doses of Moderna's COVID-19 vaccine were shipped globally, with approximately 25% of those doses shipped to low- and middle-income countries.

In the European Union, the Company's COVID-19 vaccine and booster are approved for use by the European Commission for active immunization to prevent COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older. To date, the European Commission has ordered 460 million doses of Moderna's COVID-19 vaccine, including boosters and the ability to purchase other COVID-19 vaccine candidates from Moderna's pipeline. Purchase under this agreement is subject to regulatory approval of the booster vaccine candidates by the European Medicines Agency (EMA).

About Moderna's Strategic Pillars

Moderna's has four strategic pillars guiding the Company's focus and impact for 2022 and beyond. Our strategic pillars are:

• Developing a pan-respiratory annual booster vaccine and continuously customizing it. A pan-respiratory annual single booster vaccine covering multiple viruses, such as COVID-19, Flu, and Respiratory Syncytial Virus, could create value for the healthcare system through compliance, convenience to the customer (one vs. three injections), and reduction in vaccine administration cost
• Developing first-in-class vaccines against latent viruses for which there are no approved vaccines today. Latent viruses infect the body, lay dormant, and do not replicate but possess the capacity to activate, causing disease. In addition, new emerging evidence highlights that latent viral infections may have yet unknown negative effects. Moderna has clinical candidates in development for several latent viruses, including Epstein-Barr Virus (Phase 1), human immunodeficiency virus (Phase 1), and Cytomegalovirus (Phase 3)
• Developing therapeutics based on mRNA-encoded proteins across oncology, cardiovascular, auto-immune disorders, and rare genetic diseases
• Developing therapeutics based on mRNA-encoded gene-editing enzymes

About Moderna

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 118,92$, was einem Rückgang von -2,69% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

UBS

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer